Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 9.7% during trading on Monday . The company traded as low as C$0.28 and last traded at C$0.28. Approximately 394,482 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 686,639 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The company’s fifty day moving average is C$0.11 and its two-hundred day moving average is C$0.08. The firm has a market cap of C$23.52 million, a price-to-earnings ratio of -13.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What is Put Option Volume?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Stock Dividend Cuts Happen Are You Ready?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
